Simian virus 40 transformation, malignant mesothelioma and brain tumors

Expert Review of Respiratory Medicine

Volumn 5, Issue 5, 2011, Pages 683-697

  Qi, Fang ^a,b   Carbone, Michele ^a,c   Yang, Haining ^a,c   Gaudino, Giovanni ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

brain tumor; malignant mesothelioma; SV40; Tag; tag; transformation

Indexed keywords

ASBESTOS; VACCINE; VIRUS DNA;

ASTROCYTE; BRAIN TUMOR; CARCINOGENICITY; CELL IMMORTALIZATION; CELL TRANSFORMATION; DISEASE ASSOCIATION; DRUG CONTAMINATION; EPIDEMIC; HUMAN; LIFE CYCLE; MESOTHELIOMA; NONHUMAN; PATHOGENESIS; POPULATION RESEARCH; REVIEW; RNA VIRUS INFECTION; SIMIAN VIRUS 40; VIRUS GENOME;

EID: 80053369730     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.51     Document Type: Review

References (135)

1. Sweet BH, Hilleman MR. The vacuolating virus, S.V. 40. Proc. Soc. Exp. Biol. Med. 105, 420-427 (1960).
2. Poulin DL, DeCaprio JA. Is there a role for SV40 in human cancer? J. Clin. Oncol. 24(26), 4356-4365 (2006). (Pubitemid 46630795)
3. Patel NC, Halvorson SJ, Sroller V et al. Viral regulatory region effects on vertical transmission of polyomavirus SV40 in hamsters. Virology 386(1), 94-101 (2009).
4. Nakanishi A, Itoh N, Li PP, Handa H, Liddington RC, Kasamatsu H. Minor capsid proteins of simian virus 40 are dispensable for nucleocapsid assembly and cell entry but are required for nuclear entry of the viral genome. J. Virol. 81(8), 3778-3785 (2007). (Pubitemid 46586875)
5. Kawano MA, Inoue T, Tsukamoto H et al. The VP2/VP3 minor capsid protein of simian virus 40 promotes the in vitro assembly of the major capsid protein VP1 into particles. J. Biol. Chem. 281(15), 10164-10173 (2006). (Pubitemid 43864552)
6. Carswell S, Alwine JC. Simian virus 40 agnoprotein facilitates perinuclear-nuclear localization of VP1, the major capsid protein. J. Virol. 60(3), 1055-1061 (1986). (Pubitemid 17179282)
7. Daniels R, Sadowicz D, Hebert DN. A very late viral protein triggers the lytic release of SV40. PLoS Pathog. 3(7), e98 (2007).
8. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. J. Natl Cancer Inst. 91(2), 119-134 (1999). (Pubitemid 29042689)
9. Stewart AR, Lednicky JA, Butel JS. Sequence analyses of human tumor-associated SV40 DNAs and SV40 viral isolates from monkeys and humans. J. Neurovirol. 4(2), 182-193 (1998). (Pubitemid 28167493)
10. Peden K, Sheng L, Omeir R et al. Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s. Virology 370(1), 63-76 (2008). (Pubitemid 350179902)
11. Zhang L, Qi F, Gaudino G et al. Tissue tropism of SV40 transformation of human cells: role of the viral regulatory region and of cellular oncogenes. Genes Cancer 1(10), 1008-1020 (2011).
12. Ewers H, Romer W, Smith AE et al. GM1 structure determines SV40-induced membrane invagination and infection. Nat. Cell. Biol. 12(1), 11-18; suppl. 11-12 (2010).
13. Atwood WJ, Norkin LC. Class I major histocompatibility proteins as cell surface receptors for simian virus 40. J. Virol. 63(10), 4474-4477 (1989). (Pubitemid 19229453)
14. Schelhaas M, Malmstrom J, Pelkmans L et al. Simian virus 40 depends on ER protein folding and quality control factors for entry into host cells. Cell 131(3), 516-529 (2007). (Pubitemid 350017762)
15. Nakanishi A, Li PP, Qu Q, Jafri QH, Kasamatsu H. Molecular dissection of nuclear entry-competent SV40 during infection. Virus Res. 124(1-2), 226-230 (2007). (Pubitemid 46216558)
16. Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat. Rev. Cancer 2(12), 957-964 (2002 (Pubitemid 37328897)
17. Wiley SR, Kraus RJ, Zuo F, Murray EE, Loritz K, Mertz JE. SV40 early-to-late switch involves titration of cellular transcriptional repressors. Genes Dev. 7(11), 2206-2219 (1993).
18. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 68(4), 1022-1029 (2008). (Pubitemid 351272219)
19. Porcu P, Grana X, Li S et al. An E2F binding sequence negatively regulates the response of the insulin-like growth factor 1 (IGF-I) promoter to simian virus 40T antigen and to serum. Oncogene 9(8), 2125-2134 (1994). (Pubitemid 24228660)
20. Chen H, Campisi J, Padmanabhan R. SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor. J. Biol. Chem. 271(24), 13959-13967 (1996). (Pubitemid 26190285)
21. Cacciotti P, Libener R, Betta P et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc. Natl Acad. Sci. USA 98(21), 12032-12037 (2001). (Pubitemid 32959821)
22. Bocchetta M, Miele L, Pass HI, Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40- transformed human mesothelial cells. Oncogene 22(1), 81-89 (2003). (Pubitemid 36152886)
23. Okubo E, Lehman JM, Friedrich TD. Negative regulation of mitotic promoting factor by the checkpoint kinase chk1 in simian virus 40 lytic infection. J. Virol. 77(2), 1257-1267 (2003). (Pubitemid 36055549)
24. Gordon-Shaag A, Ben-Nun-Shaul O, Roitman V, Yosef Y, Oppenheim A. Cellular transcription factor Sp1 recruits simian virus 40 capsid proteins to the viral packaging signal, ses. J. Virol. 76(12), 5915-5924 (2002). (Pubitemid 34556286)
25. Oppenheim A, Ben-Nun-Shaul O, Mukherjee S, Abd-El-Latif M. SV40 assembly in vivo and in vitro. Comput. Math. Methods Med. 9(3-4), 265-276 (2008).
26. Manley K, OHara BA, Atwood WJ. Nuclear factor of activated T-cells (NFAT) plays a role in SV40 infection. Virology 372(1), 48-55 (2008). (Pubitemid 351215462)
27. Khalili K, Sariyer IK, Safak M. Small tumor antigen of polyomaviruses: role in viral life cycle and cell transformation. J. Cell. Physiol. 215(2), 309-319 (2008). (Pubitemid 351468942)
28. Kriegler M, Perez CF, Hardy C, Botchan M. Transformation mediated by the SV40 T antigens: separation of the overlapping SV40 early genes with a retroviral vector. Cell 38(2), 483-491 (1984). (Pubitemid 14022041)
29. Shera KA, Shera CA, McDougall JK. Small tumor virus genomes are integrated near nuclear matrix attachment regions in transformed cells. J. Virol. 75(24), 12339-12346 (2001). (Pubitemid 33115906)
30. Liu J, Kaur G, Zhawar VK et al. Role of SV40 integration site at chromosomal interval 1q21.1 in immortalized CRL2504 cells. Cancer Res. 69(19), 7819-7825 (2009).
31. Jensen F, Koprowski H, Ponten JA. Rapid transformation of human fibroblast cultures by simian virus. Proc. Natl Acad. Sci. USA 50, 343-348 (1963).
32. Shein HM. Transformation of astrocytes and destruction of spongioblasts induced by a simian tumor virus (SV40) in cultures of human fetal neuroglia. J. Neuropathol. Exp. Neurol. 26(1), 60-76 (1967).
33. Ponten J, Jensen F, Koprowski H. Morphological and virological investigation of human tissue cultures transformed with SV40. J. Cell. Comp. Physiol. 61, 145-163 (1963).
34. Foddis R, De Rienzo A, Broccoli D et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 21(9), 1434-1442 (2002). (Pubitemid 34214508)
35. Carbone M, Pannuti A, Zhang L, Testa JR, Bocchetta M. A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells. Cancer Res. 68(22), 9488-9496 (2008
36. Bocchetta M, Carbone M. SV40-mediated oncogenesis. In:Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Pass H, Vogelzan N, Carbone M (Eds). Springer, New York, NY, USA, 34-59 (2005).
37. De Luca A, Baldi A, Esposito V et al. The retinoblastoma gene family pRb/ p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat. Med. 3(8), 913-916 (1997). (Pubitemid 27353454)
38. Bocchetta M, Di Resta I, Powers A et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc. Natl Acad. Sci. USA 97(18), 10214-10219 (2000).
39. Sroller V, Vilchez RA, Stewart AR, Wong C, Butel JS. Influence of the viral regulatory region on tumor induction by simian virus 40 in hamsters. J. Virol. 82(2), 871-879 (2008).
40. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am. J. Pathol. 142(5), 1524-1533 (1993). (Pubitemid 24058139)
41. Brinster RL, Chen HY, Messing A, van Dyke T, Levine AJ, Palmiter RD. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37(2), 367-379 (1984). (Pubitemid 14079032)
42. Palmiter RD, Chen HY, Messing A, Brinster RL. SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice. Nature 316(6027), 457-460 (1985). (Pubitemid 16238457)
43. Lee YC, Asa SL, Drucker DJ. Glucagon gene 5-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J. Biol. Chem. 267(15), 10705-10708 (1992).
44. Saenz Robles MT, Pipas JM. T antigen transgenic mouse models. Semin. Cancer Biol. 19(4), 229-235 (2009).
45. Hanahan D. Heritable formation of pancreatic b-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315(6015), 115-122 (1985). (Pubitemid 15064530)
46. Wikenheiser KA, Clark JC, Linnoila RI, Stahlman MT, Whitsett JA. Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res. 52(19), 5342-5352 (1992
47. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl Acad. Sci. USA 91(23), 11236-11240 (1994). (Pubitemid 24349661)
48. Greenberg NM, DeMayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92(8), 3439-3443 (1995).
49. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Curr. Protoc. Immunol. Chapter 20, Unit 20.5 (2001).
50. Santarelli R, Tzeng YJ, Zimmermann C, Guhl E, Graessmann A. SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals. Oncogene 12(3), 495-505 (1996). (Pubitemid 26059643)
51. Perez-Stable C, Altman NH, Brown J, Harbison M, Cray C, Roos BA. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab. Invest. 74(2), 363-373 (1996). (Pubitemid 26072079)
52. Garabedian EM, Roberts LJ, McNevin MS, Gordon JI. Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice. J. Biol. Chem. 272(38), 23729-23740 (1997). (Pubitemid 27410949)
53. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl Acad. Sci. USA 95(26), 15382-15387 (1998). (Pubitemid 29018707)
54. Asamoto M, Hokaiwado N, Cho YM et al. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res. 61(12), 4693-4700 (2001). (Pubitemid 32691878)
55. Masumori N, Thomas TZ, Chaurand P et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61(5), 2239-2249 (2001). (Pubitemid 32692054)
56. Gabril MY, Onita T, Ji PG et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther. 9(23), 1589-1599 (2002). (Pubitemid 35414521)
57. Hicks SM, Vassallo JD, Dieter MZ et al. Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology 187(2-3), 217-228 (2003). (Pubitemid 36423314)
58. Garson K, Macdonald E, Dube M, Bao R, Hamilton TC, Vanderhyden BC. Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. J. Soc. Gynecol. Investig. 10(4), 244-250 (2003). (Pubitemid 36579248)
59. Lou DQ, Molina T, Bennoun M et al. Conditional hepatocarcinogenesis in mice expressing SV 40 early sequences. Cancer Lett. 229(1), 107-114 (2005). (Pubitemid 41262546)
60. Grippo PJ, Sandgren EP. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am. J. Pathol. 157(3), 805-813 (2000). (Pubitemid 32109373)
61. Robinson C, van Bruggen I, Segal A et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 66(22), 10786-10794 (2006 (Pubitemid 44876974)
62. K̈bbert C, Mollmann C, Schafers M et al. Transgenic model of cardiac rhabdomyosarcoma formation. J. Thorac. Cardiovasc. Surg. 136(5), 1178-1186 (2008).
63. ter Brugge PJ, Ta VB, de Bruijn MJ et al. A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood 114(1), 119-127 (2009).
64. Stahl S, Sacher T, Bechtold A et al. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol. Lett. 123(1), 31-37 (2009).
65. Iwakura H, Ariyasu H, Li Y et al. A mouse model of ghrelinoma exhibited activated growth hormone-insulin-like growth factor I axis and glucose intolerance. Am. J. Physiol. Endocrinol. Metab. 297(3), E802-E811 (2009).
66. Pass HI, Vogelzang N, Hahn SM, Carbone M. Benign and malignant mesothelioma. In:Cancer, Principles & Practice of Oncology. De Vita VT, Hellmann S, Rosemberg SA (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 1687-1715 (2005).
67. Carbone M, Ly BH, Dodson RF et al. Malignant mesothelioma: Facts, myths and hypotheses. J. Cell. Physiol. DOI: 10.1002/ jcp.22724 (2011) (Epub ahead of print).
68. Ramos-Nino ME, Testa JR, Altomare DA et al. Cellular and molecular parameters of mesothelioma. J. Cell. Biochem. 98(4), 723-734 (2006). (Pubitemid 43993391)
69. Cacciotti P, Barbone D, Porta C et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 65(12), 5256-5262 (2005). (Pubitemid 40827336)
70. Gee GV, Stanifer ML, Christensen BC et al. SV40 associated miRNAs are not detectable in mesotheliomas. Br. J. Cancer 103(6), 885-888 (2010).
71. Cacciotti P, Strizzi L, Vianale G et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am. J. Respir. Cell Mol. Biol. 26(2), 189-193 (2002). (Pubitemid 34107872)
72. Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193(4), 468-475 (2001). (Pubitemid 32266815)
73. Kroczynska B, Cutrone R, Bocchetta M et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc. Natl Acad. Sci. USA 103(38), 14128-14133 (2006 (Pubitemid 44452991)
74. Pietruska JR, Kane AB. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res. 67(8), 3637-3645 (2007). (Pubitemid 46762148)
75. Yang H, Bocchetta M, Kroczynska B et al. TNF-a inhibits asbestos-induced cytotoxicity via a NF-kB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc. Natl Acad. Sci. USA 103(27), 10397-10402 (2006). (Pubitemid 44051178)
76. Sartore-Bianchi A, Gasparri F, Galvani A et al. Bortezomib inhibits nuclear factor-kB dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. 13(19), 5942-5951 (2007). (Pubitemid 47583922)
77. Yang H, Rivera Z, Jube S et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl Acad. Sci. USA 107(28), 12611-12616 (2010
78. Henzi T, Blum WV, Pfefferli M, Kawecki TJ, Salicio V, Schwaller B. SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am. J. Pathol. 174(6), 2324-2336 (2009).
79. Comar M, Rizzardi C, de Zotti R et al. SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma. Cancer Res. 67(18), 8456-8459 (2007). (Pubitemid 47437418)
80. Zekri AR, Bahnassy AA, Mohamed WS et al. Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathol. Int. 57(8), 493-501 (2007). (Pubitemid 47030133)
81. Degiovanni D, Pesce B, Pondrano N. Asbestos in Italy. Int. J. Occup. Environ. Health 10(2), 193-197 (2004). (Pubitemid 38780379)
82. Pancaldi C, Balatti V, Guaschino R et al. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J. Infect. 58(1), 53-60 (2009).
83. Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M. Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 318(1), 1-9 (2004). (Pubitemid 38234254)
84. Cutrone R, Lednicky J, Dunn G et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 65(22), 10273-10279 (2005). (Pubitemid 41743719)
85. Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V. Clinical and serologic responses in volunteers given vacuolating virus (SV-40) by respiratory route. Proc. Soc. Exp. Biol. Med. 108, 56-59 (1961).
86. Horvath BL, Fornosi F. Excretion of SV-40 virus after oral administration of contaminated polio vaccine. Acta Microbiol. Acad. Sci. Hung. 11, 271-275 (1964).
87. Li RM, Branton MH, Tanawattanacharoen S, Falk RA, Jennette JC, Kopp JB. Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J. Am. Soc. Nephrol. 13(9), 2320-2330 (2002). (Pubitemid 34925242)
88. Patel NC, Vilchez RA, Killen DE et al. Detection of polyomavirus SV40 in tonsils from immunocompetent children. J. Clin. Virol. 43(1), 66-72 (2008).
89. Vanchiere JA, Nicome RK, Greer JM, Demmler GJ, Butel JS. Frequent detection of polyomaviruses in stool samples from hospitalized children. J. Infect. Dis. 192(4), 658-664 (2005). (Pubitemid 41099315)
90. Vanchiere JA, Abudayyeh S, Copeland CM, Lu LB, Graham DY, Butel JS. Polyomavirus shedding in the stool of healthy adults. J. Clin. Microbiol. 47(8), 2388-2391 (2009).
91. Klein G, Powers A, Croce C. Association of SV40 with human tumors. Oncogene 21(8), 1141-1149 (2002). (Pubitemid 34185230)
92. Carbone M, Pass HI, Rizzo P et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9(6), 1781-1790 (1994). (Pubitemid 24163409)
93. Testa JR, Carbone M, Hirvonen A et al. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res. 58(20), 4505-4509 (1998). (Pubitemid 28480603)
94. Ramael M, Nagels J, Heylen H et al. Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma. Eur. Respir. J. 14(6), 1381-1386 (1999). (Pubitemid 30019537)
95. Shivapurkar N, Wiethege T, Wistuba II et al. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J. Cell. Biochem. 76(2), 181-188 (1999). (Pubitemid 30030766)
96. De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J. Cell. Biochem. 84(3), 455-459 (2002). (Pubitemid 34111180)
97. Priftakis P, Bogdanovic G, Hjerpe A, Dalianis T. Presence of simian virus 40 (SV40) is not frequent in Swedish malignant mesotheliomas. Anticancer Res. 22(3), 1357-1360 (2002). (Pubitemid 34839138)
98. Cristaudo A, Foddis R, Vivaldi A et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res. 65(8), 3049-3052 (2005). (Pubitemid 40524583)
99. Leithner A, Weinhaeusel A, Windhager R et al. Absence of SV40 in Austrian tumors correlates with low incidence of mesotheliomas. Cancer Biol. Ther. 1(4), 375-379 (2002).
100. Hubner R, Van Marck E. Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura (Belgium). Cancer Biol. Ther 13(2), 121-129 (2002). (Pubitemid 34229677)
101. Mayall F, Barratt K, Shanks J. The detection of Simian virus 40 in mesotheliomas from New Zealand and England using real time FRET probe PCR protocols. J. Clin. Pathol. 56(10), 728-730 (2003). (Pubitemid 37243929)
102. Brousset P, Sabatier J, Galateau-Salle F. SV40 infection in human cancers. Ann. Oncol. 16(7), 1212-1213 (2005).
103. Weiss AF, Portmann R, Fischer H, Simon J, Zang KD. Simian virus 40-related antigens in three human meningiomas with defined chromosome loss. Proc. Natl Acad. Sci. USA 72(2), 609-613 (1975).
104. Weiss AF, Zang KD, Birkmayer GD, Miller F. SV 40 related papova-viruses in human meningiomas. Acta Neuropathol. 34(2), 171-174 (1976).
105. Vilchez RA, Butel JS. SV40 in human brain cancers and non-Hodgkins lymphoma. Oncogene 22(33), 5164-5172 (2003). (Pubitemid 37059597)
106. Wang J, Garcea RL. Simian virus 40 DNA sequences in human brain and bone tumours. Dev. Biol. Stand. 94, 13-21 (1998).
107. Huang H, Reis R, Yonekawa Y, Lopes JM, Kleihues P, Ohgaki H. Identification in human brain tumors of DNA sequences specific for SV40 large T antigen. Brain Pathol. 9(1), 33-42 (1999).
108. Rollison DE, Utaipat U, Ryschkewitsch C et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int. J. Cancer 113(5), 769-774 (2005). (Pubitemid 40101258)
109. Kim JY, Koralnik IJ, LeFave M, Segal RA, Pfister LA, Pomeroy SL. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro. Oncol. 4(3), 165-170 (2002 (Pubitemid 35214752)
110. Montesinos-Rongen M, Besleaga R, Heinsohn S et al. Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. Virchows Arch. 444(5), 436-438 (2004). (Pubitemid 38703760)
111. Sabatier J, Uro-Coste E, Benouaich A et al. Immunodetection of SV40 large T antigen in human central nervous system tumours. J. Clin. Pathol. 58(4), 429-431 (2005). (Pubitemid 40516180)
112. Bergsagel DJ, Finegold MJ, Butel JS, Kupsky WJ, Garcea RL. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N. Engl. J. Med. 326(15), 988-993 (1992).
113. Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene 20(33), 4441-4449 (2001). (Pubitemid 32772426)
114. Meneses A, Lopez-Terrada D, Zanwar P et al. Lymphoproliferative disorders in Costa Rica and simian virus 40. Haematologica 90(12), 1635-1642 (2005). (Pubitemid 41814987)
115. Zekri AR, Mohamed W, Bahnassy A et al. Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies. Leuk. Lymphoma 48(9), 1828-1834 (2007). (Pubitemid 47386719)
116. Amara K, Trimeche M, Ziadi S et al. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int. J. Cancer 121(12), 2693-2702 (2007). (Pubitemid 350136414)
117. Heinsohn S, Scholz R, Kabisch H. SV40 and p53 as team players in childhood lymphoproliferative disorders. Int. J. Oncol. 38(5), 1307-1317 (2011).
118. Yamamoto H, Nakayama T, Murakami H et al. High incidence of SV40-like sequences detection in tumour and peripheral blood cells of Japanese osteosarcoma patients. Br. J. Cancer 82(10), 1677-1681 (2000). (Pubitemid 30229578)
119. Heinsohn S, Szendroi M, Bielack S, Stadt UZ, Kabisch H. Evaluation of SV40 in osteosarcoma and healthy population: a Hungarian-German study. Oncol. Rep. 21(2), 289-297 (2009).
120. Hachana M, Trimeche M, Ziadi S, Amara K, Korbi S. Evidence for a role of the Simian virus 40 in human breast carcinomas. Breast Cancer Res. Treat. 113(1), 43-58 (2009).
121. Campello C, Comar M, Zanotta N, Minicozzi A, Rodella L, Poli A. Detection of SV40 in colon cancer: a molecular case-control study from northeast Italy. J. Med. Virol. 82(7), 1197-1200 (2010).
122. Sangar D, Pipkin PA, Wood DJ, Minor PD. Examination of poliovirus vaccine preparations for SV40 sequences. Biologicals 27(1), 1-10 (1999). (Pubitemid 29381112)
123. Pershouse MA, Heivly S, Girtsman T. The role of SV40 in malignant mesothelioma and other human malignancies. Inhal. Toxicol. 18(12), 995-1000 (2006). (Pubitemid 44294149)
124. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364(9440), 1157-1166 (2004). (Pubitemid 39296603)
125. Gordon GJ, Chen CJ, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R. Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines. Oncol. Rep. 9(3), 631-634 (2002).
126. Jin M, Sawa H, Suzuki T et al. Investigation of simian virus 40 large T antigen in 18 autopsied malignant mesothelioma patients in Japan. J. Med. Virol. 74(4), 668-676 (2004). (Pubitemid 39426110)
127. Aoe K, Hiraki A, Murakami T et al. Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan. Cancer Sci. 97(4), 292-295 (2006).
128. Hmeljak J, Kern I, Cor A. No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia. Tumori 96(5), 667-673 (2010).
129. Stratton K, Almario DA; IOM. Immunization safety review: SV40 contamination of polio vaccines and cancer. In: Institute of Medicine (IOM). The National Academy of Sciences, Washington, DC, USA (2002).
130. Liu J, Li H, Nomura K, Dofuku R, Kitagawa T. Cytogenetic analysis of hepatic cell lines derived from SV40-T antigen gene-harboring transgenic mice. Cancer Genet. Cytogenet. 55(2), 207-216 (1991).
131. Carbone M, Rdzanek MA, Rudzinski JJ et al. SV40 detection in human tumor specimens. Cancer Res. 65(21), 10120-10121 (2005). (Pubitemid 41541495)
132. Carbone M, Rizzo P, Procopio A et al. SV40-like sequences in human bone tumors. Oncogene 13(3), 527-535 (1996). (Pubitemid 26283849)
133. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 5(3), e1000363 (2009
134. Ferber D. Public health. Creeping consensus on SV40 and polio vaccine. Science 298(5594), 725-727 (2002). (Pubitemid 35231498)
135. Cantalupo PG, Saenz-Robles MT, Rathi AV et al. Cell-type specific regulation of gene expression by simian virus 40 T antigens. Virology 386(1), 183-191 (2009